GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
- Conditions
- HIV Pre-exposure Prophylaxis
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT07047716
Study of GS-3242 in Participants With HIV-1
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT07001319
- Locations
- 🇺🇸
Quest Clinical Research,Substudy-05, San Francisco, California, United States
🇺🇸Washington Health Institute,Substudy-05, Washington, District of Columbia, United States
🇺🇸Midland Florida Clinical Research Center, LLC,Substudy-05, DeLand, Florida, United States
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Sacituzumab Govitecan-hziy (SG)
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06926920
- Locations
- 🇺🇸
Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles, California, United States
Study of GS-0151 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 75
- Registration Number
- NCT06902519
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Clinical Research of West Florida, Inc, Clearwater, Florida, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 695
- Registration Number
- NCT06801834
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Linyi Cancer Hospital, Linyi, China
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 4
- Registration Number
- NCT06784973
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Midway Medical Clinic, Oneonta, Alabama, United States
🇺🇸Cohen Children's Medical Center Pharmacy New Pavillion, Phoenix, Arizona, United States
Expanded Access for Bulevirtide
- Conditions
- Chronic Hepatitis Delta Virus Infection
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT06780579
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 12
- Registration Number
- NCT06749054
- Locations
- 🇺🇸
Grady Health System, Ponce De Leon Center, Atlanta, Georgia, United States
🇿🇦FAMCRU, Cape Town, South Africa
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, South Africa
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06727565
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇲🇾Sarawak General Hospital, Sarawak, Malaysia
A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain
- Conditions
- Breast Cancer
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT06683482
- Locations
- 🇪🇸
Salvetti & Llombart Sl, Barcelona, Catalonia, Spain